BioPhorum Supply Chain to Patient

BioPhorum Supply Chain to Patient
Product Description

Our mission: To transform the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration.
Why collaborate? The pharmaceutical outbound supply chain is facing capacity constraints more challenging than ever before. Increasing costs and greater complexity, overlaid with new modalities has prompted new thinking and a fresh approach.

Industry collaboration can accelerate improvements and transform performance in a way that is not possible when working independently. Learning from each other, challenging current thinking, and re-imagining the supply chain can reduce costs and increase efficiency.

BioPhorum

  • GB
  • 2021
    On CPHI since
  • 100 - 249
    Employees
Company types
Other
Primary activities
Biopharmaceutical
Medical Devices
Other
Regulatory Affairs
Supply Chain
Specifications

BioPhorum

  • GB
  • 2021
    On CPHI since
  • 100 - 249
    Employees
Company types
Other
Primary activities
Biopharmaceutical
Medical Devices
Other
Regulatory Affairs
Supply Chain

More Products from BioPhorum (2)

  • BioPhorum Technology Roadmapping

    Product BioPhorum Technology Roadmapping

    Technology Roadmapping (TR) is a collaborative technology management process that accelerates innovation and development of the manufacturing processes of the future.Here biomanufacturers, supply partners, engineering partners and regional innovation hubs build and communicate the roadmap strategy. In prio...
  • BioPhorum Sustainability

    Product BioPhorum Sustainability

    Our mission: To act as a voice of the industry to enable delivery of the industry’s sustainability ambition quickly and effectively. To lead innovative teams who have the capability and credibility to create consensus and ultimately drive real change that benefits people and planet.

    Why col...

BioPhorum resources (2)

  • News CPHI Sustainability Trend Report: Towards a Greener Future

    CPHI releases its Sustainability Trend Report focusing on carbon emissions in the supply chain and working towards a greener future in the pharmaceutical industry.
  • Technical Data Digital Technology Roadmap

    The Digital Plant Maturity Model (DPMM)1 describes one characteristic of a Level 5: Adaptive Plant as “In-line, real-time, continuous, closed-loop, process verification and control with automated realtime quality release”. This is the pinnacle of ‘Industry 4.0’, a term coined around 2011 to outline the advantages that a wide array of digital technologies running in concert can bring to manufacturing and critical facilities. For most pharmaceutical manufacturers, the strategic advancements these technologies can deliver have not been realized.